NeuroSense Granted Patents In Europe, Japan, And Israel For Its ALS Drug PrimeC
Patents valid through 2038Clinical topline results from Phase 2b ALS trial expected in H2 2023CAMBRIDGE, Mass., Sept. 19, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a